MENU

Company news

ImmuneOnco Held 2021 Shareholders’ Conference

Date:2021-06-17 Views:277

      June 16, 2021, Shanghai, China ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") 2021 annual meeting of shareholders was successfully held at "47" Building, Lane 908, Ziping Road. The founder and chairman of ImmuneOnco, Dr. Tian Wenzhi, as well as the senior management team attended the meeting with shareholders or their representatives.




      Dr. Tian Wenzhi, addressed and reviewed the drug development and business achievements during last year and reported plans for all aspects of new drug research and development, project advancement, and future developing tactics.

      The management team of ImmuneOnco also presented on special fields such as technical platform construction, clinical research progress, business cooperation progress, and financial budgeting.




      The meeting scheduled a discussion about most concerned topics for shareholders so as to make face to face   discussion between investors and developers. The communication in detail will benefit on project progress, product development, team build-up, capital-market attraction and others about the future developmental plans. The shareholders actively offered advices and suggestions for development of the company, and at the same time, expressed their full confidence in future development of ImmuneOnco, and determined to support ImmuneOnco, and work closely with the company to create a brilliant future.





About ImmuneOnco

Founded in June 2015 in the Zhangjiang Hi-Tech Park of the China (Shanghai) Pilot Free Trade Zone, ImmuneOnco focuses on development and research of anti-tumor immunotherapy products, including bispecific antibody-traps (mAb-Traps), novel recombinant proteins, and target-activated NK cell therapy. Our compounds aim to activate patients’own immune system to exert anti-tumor effects, and ultimately inhibit endless growth of tumor cells and reverse malignant symptoms, so that patients can gradually return to being healthy. Currently, several new anti-tumor products are in clinical development stage. ImmuneOnco is recognized by authorities as one of the ‘Top 50 Start-up Enterprises with the Most Investment Potential in Shanghai’ in 2016, the "Excellent Enterprise" in the 2017 China Innovation and Entrepreneurship Competition, and one of the winners of the "Enterprise Excellence Award" of Shanghai Science and Technology Entrepreneurship in 2017.


For further cooperation, please contact

Address: Room 502, 1043 HaLei Road, Pudong New Area, Shanghai, China

Building 7, Lane 908, Ziping Road, Pudong New Area, Shanghai, China

Tel. + 86 21 5835 6573

website: www.immuneonco.com